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EXTENSIVE DEEP VENOUS THROMBOSIS 
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MANIFESTATION OF A RARE VENOUS ANOMALY – 
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SUMMARY – Although venous thromboembolism (VTE) including deep venous thrombosis 
(DVT) and pulmonary embolism is a major health problem in the world, it is an infrequent disease 
among young people. It is always mandatory to look at the underlying conditions for VTE, and in 
young patients, inherited prothrombotic factors should also be evaluated, especially in case of unpro-
voked VTE. Anomalies of inferior vena cava (IVC) are very rare in the general population. In this case 
report we describe rare occurrence of extensive DVT in a young male patient with rare anomaly of 
IVC – duplication of IVC – as a predisposition factor for DVT. Physicians need to be reminded of the 
IVC anomalies that should be considered in young patients with idiopathic DVT of lower extremity, 
which may require extended anticoagulant treatment.
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Introduction
Venous thromboembolism (VTE), including deep 
venous thrombosis (DVT) and pulmonary embolism 
(PE), is a frequent and important health problem in 
the world, as well as in Croatia, with estimated inci-
dence between 1 and 2 per 1000 individuals per year1-8. 
VTE is a multicausal disease with many interactions 
between diff erent acquired (immobilization, surgery, 
trauma, cancer, autoimmune disorders, pregnancy, oral 
contraceptive use, long distance airplane fl ight, etc.) 
and inherited prothrombotic factors (FV Leiden and 
FII 20210A mutations, defi ciencies of protein C, S 
and antithrombin, and elevations of procoagulant fac-
tors)8. Although it is in general a frequent disease, 
VTE is rare among young people; the incidence of 
VTE is less than 5 fi rst-time VTE per 100,000 per 
year among people younger than 15 years but increases 
sharply to 450-600 per 100,000 per year among people 
aged 80 years or older1,3,5,8. In the most recent study of 
VTE incidence in the Croatian population, just 8.9% 
of all patients with newly diagnosed VTE were pa-
tients aged 45 years or younger8.
It is mandatory to look at the underlying main 
cause responsible for VTE occurrence. In younger pa-
tients, inherited thrombophilia screening should also 
be considered, especially if VTE occurs recurrently or 
without obvious acquired reason9.
Congenital anomalies of the inferior vena cava 
(IVC) such as hypoplasia, duplication of the IVC or 
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the absence of the infrahepatic IVC are very rare in the 
general population, described in a proportion of 0.2%-
1%10-12. Th ese anomalies are usually asymptomatic and 
mostly an incidental fi nding. However, lower extremity 
ulcer with or without prior DVT might be frequent in 
later stages of this condition. In addition, in patients 
younger than 30 years presenting with DVT, the inci-
dence of IVC anomalies increases to up to 5%13,14.
In this case report, we describe the unusual occur-
rence of extensive DVT in a young male patient, in 
association with duplicated IVC as a risk factor in the 
development of DVT.
Case Report
A 31-year-old Caucasian male with no signifi cant 
previous medical history was admitted to the hospital 
through the emergency service because of the color 
duplex ultrasound (US) confi rmed extensive DVT of 
the left popliteal, femoral superfi cial and common 
femoral vein. Physical examination revealed a pitting 
edema of the left leg with tenderness, a signifi cant size 
diff erence between circumferences of his legs, and nor-
mal arterial pulsations in both lower extremities. Th e 
rest of physical examination was normal. He subse-
quently started receiving low molecular weight hepa-
rin (LMWH) together with warfarin.
Th e patient denied recent immobilization, trauma, 
surgery or any other recent serious medical condition. 
He denied recent distant travel. Th e only known pre-
disposing prothrombotic risk factor was tobacco use; 
he smoked about 20 cigarettes per day. His personal 
and family history of clotting disorders or peripheral 
vascular disease was negative. Th erefore, the following 
extended diagnostic work-up was performed to rule 
out any underlying condition.
Due to nonspecifi c infi ltration on chest radiogra-
phy and in order to exclude a malignant disease, multi-
slice computed tomography (MSCT) of the neck, 
chest, abdomen and pelvis with intravenous contrast 
was performed. Th e aforementioned imaging method 
showed duplication of the IVC. Both IVCs ran paral-
lel to each other bordering the aorta, with the left-
sided IVC ascending to the level of the left renal vein. 
Th e left IVC, the medial part of the left renal vein, the 
proximal part of the left suprarenal vein, the left com-
mon and external iliac vein, and also the left common 
femoral vein were found to be clotted (Fig. 1 a, b, c). 
Th ere was no other signifi cant pathologic fi nding on 
MSCT scan. A vascular surgeon excluded angiosurgi-
cal treatment. Further work-up was performed. Eso-
phagogastroduodenoscopy revealed a hiatal hernia, 
refl ux esophagitis and chronic gastritis. Doppler US of 
the testicles excluded focal lesions or pathologic hy-
pervascularization, and US of the neck and thyroid 
gland showed no pathologic fi ndings either. Electro-
cardiogram and cardiac US were normal. Serum tumor 
markers (AFP, CEA, CA 19-9, PSA, NSE and CY-
FRA) were within the normal range. On the other 
hand, due to high blood glucose levels (9.2 mmol/L, 
normal 4.4-6.4 mmol/L), the patient underwent full 
endocrine work-up and was diagnosed with diabetes 
type 2. Also, serum cholesterol (5.2 mmol/L, normal 
<5 mmol/L) and low-density lipoprotein (LDL) (3.08 
mmol/L, normal <3 mmol/L) concentrations were 
slightly elevated. At fi rst, changes in diet and lifestyle 
were recommended, but later during the follow up pe-
riod he started with oral therapy for diabetes (vida-
gliptin), with good control of glucose level.
In addition, thrombophilia work-up revealed a 
high level of homocysteine (16.2 μmol/L, normal 
<13.8 μmol/L) in the blood. Other thrombophilia 
markers such as protein C, protein S and antithrombin 
activities were normal. Polymerase chain reaction 
(PCR) analysis of Factor V Leiden, FII 20210A, 
MTHFR 677, and JAK2 V617F mutations did not 
show any alterations. Lupus anticoagulant and anti-
cardiolipin antibodies were negative. Other routine 
laboratory tests for the most common autoimmune 
disorders were also negative. Th e level of beta2-micro-
globulin was also within the normal range. Control 
MSCT venography performed 11 days after the fi rst 
MSCT revealed improvement with partial regression 
of the clot (Fig. 2).
Th e patient was kept on therapeutic dose of 
LMWH because therapeutic INR range could not be 
achieved despite high doses of warfarin (15 mg of war-
farin per day). He also received folic acid and B-group 
vitamins because of hyperhomocysteinemia, and was 
recommended to take compressive stockings. He was 
followed-up in the outpatient unit regularly after dis-
charge from the hospital, with further clinical im-
provement and partial recanalization of the veins of 
the left leg on control color Doppler US, without signs 
of postthrombotic syndrome or leg ulcer. He did not 
have any bleeding side eff ects of anticoagulant therapy 
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with LMWH during 2-year follow up, with excellent 
compliance to therapy. Th e homocysteine level nor-
malized and D-dimers were continuously negative 
during the follow up period. However, because of the 
IVC anomaly as an irreversible prothrombotic risk 
 factor, he was recommended to continue with extend-
ed anticoagulation therapy. Other anticoagulant mo-
dalities were discussed with the patient, but it was de-
cided for now to continue with therapeutic doses of 
LMWH.
Discussion
Th is case report describes extensive DVT in a 
young male patient, in association with a rare anomaly 
of duplicated IVC. Although it is possible that lifelong 
asymptomatic IVC malformations can occur15, Rug-
geri et al. state that congenital anomalies of the IVC 
might be a risk factor for DVT14, and some authors 
believe that IVC malformation alone can provoke 
DVT, presumably by favoring venous stasis16,17.
Anomalies of IVC are rare in the general popula-
tion, and duplications of the IVC are a very rare fi nd-
ing in radiologic studies, with an incidence of 0.2% to 
3.0%18. Th e earliest reported case of duplication of the 
IVC was reported in 191219, the majority of later cases 
were diagnosed accidentally by imaging for other rea-
sons18, but during the last 100 years, there are just a few 
reported cases involving IVC duplication in associa-
tion with DVT10,15,17,18,20.
In general, diagnosis of IVC anomaly was in most 
of the cases established by angio-computer tomogra-
phy (angio-CT)5,21,22, and angio-CT and angio-mag-
netic resonance imaging (angio-MRI) are the imaging 
methods that can provide the diagnosis14,16,22. US is less 
used for detecting IVC anomalies and, according to 
some authors, the usefulness of US in the diagnosis of 
IVC anomalies is limited23,24, although others suggest 
US as the initial evaluation of IVC anomaly, and an-
gio-CT or angio-MRI for confi rmation of the diagno-
sis of IVC anomaly22.
Currently there are no precise guidelines available 
for the use of anticoagulation therapy in young people 
who develop VTE in association with a congenital 
IVC anomaly due to the inadequate number of pa-
Fig. 1. (a) and b) Th rombosis of the left inferior vena cava (IVC); (c) thrombosis of the common and external iliac vein.
a) b) c)
Fig. 2. Partial improvement of the clot in the left inferior 
vena cava (IVC).
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tients with these anomalies and the lack of studies of 
VTE in such circumstances. Apparently, the most ap-
propriate approach to treatment is extended anticoag-
ulation because of the presence of an irreversible risk 
factor for development of VTE. Th e possibility of re-
current VTE is high in these patients when anticoagu-
lation treatment is stopped17. Our case report is the 
fi rst one with LMWH as extended anticoagulant 
therapy in a patient with IVC duplication and exten-
sive DVT. Our patient was maintained on LMWH in 
therapeutic doses because he could not reach thera-
peutic INR even with high doses of warfarin and had 
extensive DVT requiring full anticoagulant treatment.
Studies assessing the potential complications, effi  -
cacy and safety of prolonged LMWH use were de-
signed in diff erent populations, such as cancer patients, 
pregnancy, and other25-34. Th ose studies addressed the 
possible side eff ects of extended LMWH use, such as 
bleeding and thrombocytopenia, and showed a low 
risk of major bleeding, rare heparin-induced thrombo-
cytopenia, and infrequent allergic and skin reac-
tions25-34. Transient elevations of aminotransferases 
may occur34, while an increased risk of fractures and 
osteoporosis is less clear32-34. For example, a systematic 
review and meta-analysis showed that the use of 
LMWH for 3-6 months did not increase the risk of 
fractures compared to unfractionated heparin or oral 
vitamin K antagonists (VKA), but longer exposure for 
up to 24 months was associated with a decrease in 
bone mineral density33. Another concern was patient 
compliance with daily subcutaneous administration of 
LMWH. However, published evidence shows that pa-
tient acceptance of LMWH is high25,35-36.
Regarding LMWH effi  cacy, in 11 trials conducted 
in diff erent patient populations, LMWH was as eff ec-
tive as VKA in preventing recurrent VTE, and no con-
sistent diff erences in bleeding complications were ob-
served during long-term treatment37. Several studies 
showed that in patients with cancer, VTE recurrence 
was signifi cantly reduced with LMWH compared to 
VKA25,37. Even in the newest and updated CHEST 
Antithrombotic Guideline published in 2016, for 
VTE and cancer, LMWH is suggested as long-term 
anticoagulant therapy over VKA or novel oral antico-
agulants (NOAC – dabigatran, rivaroxaban, apixaban, 
and edoxaban)38. Moreover, for recurrent VTE on a 
non-LMWH anticoagulant, LMWH is suggested, 
and for recurrent VTE on LMWH, increased dose of 
LMWH is suggested38. Th erefore, LMWH is very ef-
fective anticoagulant option with reasonably low side 
eff ects.
However, other anticoagulant modalities were also 
discussed with our patient, including novel oral anti-
coagulant drugs (NOAC). Literature data on the us-
age of NOAC in such or similar settings are still very 
limited. Reviewing the literature, we found just one 
published case report describing a patient with IVC 
atresia who developed DVT and was discharged home 
using NOAC (rivaroxaban), but after catheter-direct-
ed thrombolysis and mechanical thrombectomy39. 
Th erefore, it was decided for our patient to continue 
for now with therapeutic doses of LMWH, which he 
was taking with clinical and radiological (color Dop-
pler US) improvement, and without any bleeding 
problems.
To conclude, our case report emphasizes that phy-
sicians need to be reminded about anomalies of the 
IVC, which should be considered and thoroughly in-
vestigated in young patients with idiopathic lower ex-
tremity DVT. Such anomalies of IVC may infl uence 
decision-making in patients who develop VTE with 
the need for extended anticoagulant treatment.
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Sažetak
OPSEŽNA DUBOKA VENSKA TROMBOZA U MLADOG BOLESNIKA 
KAO PRVA MANIFESTACIJA RIJETKE VENSKE ANOMALIJE – DVOSTRUKE DONJE ŠUPLJE VENE: 
PRIKAZ SLUČAJA
D. Pulanić, E. Ranković, M. Vodanović, M. Lušić, A. Boban, S. Zupančić Šalek i D. Nemet
Iako su venske tromboembolije (VTE) koje uključuju duboku vensku trombozu (DVT) i plućnu emboliju značajan 
zdravstveni problem u svijetu, one su rijetke bolesti u mladih osoba. Uvijek je potrebno ispitati uzroke koji su doveli do na-
stanka VTE, a u mladih bolesnika potrebno je također evaluirati i nasljedne protrombotske čimbenike, osobito kod nastanka 
neprovocirane VTE. Anomalije donje šuplje vene su vrlo rijetke u općoj populaciji. U ovom prikazu slučaja opisujemo rijedak 
slučaj mladog bolesnika s opsežnom DVT i rijetkom anomalijom donje šuplje vene – dvostrukom donjom šupljom venom 
– kao čimbenikom rizika za nastanak DVT. Potrebno je podsjetiti liječnike na postojanje anomalija donje šuplje vene koje 
treba razmotriti u mladih bolesnika s idiopatskom DVT donjih ekstremiteta, što može zahtijevati dugotrajno antikoagu-
lantno liječenje.
Ključne riječi: Venska tromboembolija; Venska tromboza; Šuplja vena, donja – nenormalnosti; Antikoagulansi – terapijska pri-
mjena; Prikazi slučaja; Hrvatska
